GENFLOW BIOSCIENCES PLC (WQ5) - Total Assets
Based on the latest financial reports, GENFLOW BIOSCIENCES PLC (WQ5) holds total assets worth €468.38K EUR (≈ $547.59K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore WQ5 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
GENFLOW BIOSCIENCES PLC - Total Assets Trend (2021–2024)
This chart illustrates how GENFLOW BIOSCIENCES PLC's total assets have evolved over time, based on quarterly financial data. See GENFLOW BIOSCIENCES PLC net assets for net asset value and shareholders' equity analysis.
GENFLOW BIOSCIENCES PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
GENFLOW BIOSCIENCES PLC's total assets of €468.38K consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 72.2% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how GENFLOW BIOSCIENCES PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GENFLOW BIOSCIENCES PLC market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GENFLOW BIOSCIENCES PLC's current assets represent 99.5% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 72.2% of total assets in 2024, down from 81.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GENFLOW BIOSCIENCES PLC Competitors by Total Assets
Key competitors of GENFLOW BIOSCIENCES PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
GENFLOW BIOSCIENCES PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.61 | 2.73 | 2.73 |
| Quick Ratio | 0.61 | 2.73 | 2.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-304.53K | €854.89K | €854.89K |
GENFLOW BIOSCIENCES PLC - Advanced Valuation Insights
This section examines the relationship between GENFLOW BIOSCIENCES PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.94 |
| Latest Market Cap to Assets Ratio | 34.08 |
| Asset Growth Rate (YoY) | -64.0% |
| Total Assets | €385.91K |
| Market Capitalization | $13.15 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values GENFLOW BIOSCIENCES PLC's assets at a significant premium (34.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: GENFLOW BIOSCIENCES PLC's assets decreased by 64.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GENFLOW BIOSCIENCES PLC (2021–2024)
The table below shows the annual total assets of GENFLOW BIOSCIENCES PLC from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €385.91K ≈ $451.17K |
-63.99% |
| 2023-12-31 | €1.07 Million ≈ $1.25 Million |
-59.06% |
| 2022-12-31 | €2.62 Million ≈ $3.06 Million |
+846.47% |
| 2021-12-31 | €276.55K ≈ $323.32K |
-- |
About GENFLOW BIOSCIENCES PLC
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducin… Read more